Literature DB >> 2052299

Magnetic resonance imaging of choroidal melanoma with and without gadolinium contrast enhancement.

J B Bond1, B G Haik, F Mihara, K L Gupta.   

Abstract

Choroidal melanoma is the most common intraocular tumor and is uniquely suited for evaluation by magnetic resonance imaging (MRI) because of the paramagnetic effect of the melanin molecule. The authors performed T1-, T2-, and proton-density-weighted MRI on 34 patients with choroidal melanoma. Nineteen patients received gadolinium contrast, T1-weighted images were superior in both detecting and delineating tumors, showing increased contrast-to-noise ratios over other images. Gadolinium contrast further increased this ratio. These images are presented as evidence that gadolinium-enhanced MRI is valuable in the evaluation of choroidal melanoma.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2052299     DOI: 10.1016/s0161-6420(91)32270-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  5 in total

1.  Vascular perfusion of choroidal melanoma by 3.0 tesla magnetic resonance imaging.

Authors:  Bruce M Buerk; Jose S Pulido; Ignacio Chiong; Robert Folberg; Deepak P Edward; Mark T Duffy; Keith R Thulborn
Journal:  Trans Am Ophthalmol Soc       Date:  2004

2.  Echographic pseudoextension of uveal melanomas.

Authors:  M L Murphy; W F Mieler; D F Williams; M F Lewandowski
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-07       Impact factor: 3.117

3.  Quantification of melanin and iron content in uveal malignant melanomas and correlation with magnetic resonance image.

Authors:  J D Ferris; P A Bloom; P R Goddard; C Collins
Journal:  Br J Ophthalmol       Date:  1993-05       Impact factor: 4.638

Review 4.  Intra-orbital malignant melanoma: role of MR imaging (a case report and literature review).

Authors:  Felix Uduma Uduma; Kamga Titalom
Journal:  Glob J Health Sci       Date:  2011-12-29

5.  Magnetic resonance imaging of cyclodialysis clefts.

Authors:  S M Johnson; H M Cheng; R Pineda; P A Netland
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1997-07       Impact factor: 3.117

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.